title: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
authors.affiliation: Department of Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA. nf@gene.com
authors.forename: Napoleone
authors.initials: N
authors.lastname: Ferrara
authors.forename: Kenneth J
authors.initials: KJ
authors.lastname: Hillan
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Gerber
authors.forename: William
authors.initials: W
authors.lastname: Novotny
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D004334:Drug Administration Schedule; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab